Novel use of accelerator mass spectrometry for the quantification of low levels of systemic therapeutic recombinant protein

Lappin, Graham and Garner, R. C. and Meyers, T. and Powell, J. and Varley, P. (2006) Novel use of accelerator mass spectrometry for the quantification of low levels of systemic therapeutic recombinant protein. Journal of Pharmaceutical and Biomedical Analysis, 41 (4). pp. 1299-1302. ISSN 0731-7085

Full content URL: http://www.sciencedirect.com/science/article/pii/S...

Documents
__network.uni_staff_S2_jpartridge_1-s2.0-S0731708506001932-main.pdf
[img] PDF
__network.uni_staff_S2_jpartridge_1-s2.0-S0731708506001932-main.pdf - Whole Document
Restricted to Repository staff only

108kB
Item Type:Article
Item Status:Live Archive

Abstract

Although 14C-labelling has been routinely used for small molecules, this technique is not routinely applied to therapeutic proteins due to difficulties of incorporating the label into the protein to a sufficiently high specific activity. An analytical method known as accelerator mass spectrometry (AMS) offers an extremely sensitive method of 14C quantification, thereby enabling 14C-labeling methods to be applied to therapeutic protein detection. The therapeutic protein CAT-192 (metelimumab), a human anti-TGF�1 monocloncal antibody was manufactured in the presence of 14C-precursors resulting in a low specific activity product (1.4 14C incorporation). 14C-CAT-192 was administered to rats (1 mg/kg and 222, 22 and 2.2 dpm/kg) and serum samples were collected. 14C in serum samples from the 2.2 dpm dosing was not detectable but samples from the 22 and 2220 dpm doses were measured by AMS and by ELISA for comparison. By both ELISA and AMS bioassay, the half-lives approximated 140 h (S.E.M. 15 h). The estimates of clearance were also comparable, 7.3 and 4.6 � 10 -4 ml/h/g (S.E.M. 6.6 and 5.1 � 10 -5) for ELISA and AMS, respectively. The estimated limit of quantification (LOQ) was approximately 1 ng/ml, about 15 times lower than the ELISA LOQ of 15.6 ng/ml. © 2006 Elsevier B.V. All rights reserved.

Keywords:carbon 14, metelimumab, transforming growth factor beta antibody, acceleration, animal experiment, article, controlled study, dose response, drug clearance, drug labeling, enzyme linked immunosorbent assay, mass spectrometry, nonhuman, priority journal, protein analysis, rat, scanning electron microscopy, Animals, Antibodies, Monoclonal, Enzyme-Linked Immunosorbent Assay, Male, Rats, Rats, Sprague-Dawley, Recombinant Proteins
Subjects:F Physical Sciences > F350 Medical Physics
B Subjects allied to Medicine > B290 Pharmacology, Toxicology and Pharmacy not elsewhere classified
Divisions:College of Science > School of Pharmacy
Related URLs:
ID Code:8232
Deposited On:27 Mar 2013 15:53

Repository Staff Only: item control page